The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations

Safreed-Harmon, Kelly;Thursz, Mark;Dillon, John;El-Sayed, Manal;Lazarus, Jeffrey;et.al.
(2018) Seminars in Liver Disease — Vol. 38, n° 3, p. 1811-1892 (2018)

Files

2018_Lazarus_Semin_Liver_Dis_Final.pdf
  • Restricted Access
  • Adobe PDF
  • 363.82 KB
2018_Lazarus_Semin_Liver_Dis.pdf
  • Open Access
  • Adobe PDF
  • 460.28 KB

Details

Authors
  • Safreed-Harmon, Kelly
    Author
  • Thursz, Mark
    Author
  • Dillon, John
    Author
  • El-Sayed, Manal
    Author
  • Jadoul, MichelUCLouvain
    Author
  • Lazarus, Jeffrey
    Author
Show more
Abstract
(en) The introduction of efficacious new hepatitis C virus (HCV) treatments galvanized the World Health Organization to define ambitious targets for eliminating HCV as a public health threat by 2030. Formidable obstacles to reaching this goal can best be overcome through a micro-elimination approach, which entails pursuing elimination goals in discrete populations through multi-stakeholder initiatives that tailor interventions to the needs of these populations. Micro-elimination is less daunting, less complex, and less costly than full-scale, country-level initiatives to eliminate HCV, and it can build momentum by producing small victories that inspire more ambitious efforts. The micro-elimination approach encourages stakeholders who are most knowledgeable about specific populations to engage with each other and also promotes the uptake of new models of care. Examples of micro-elimination target populations include medical patients, people who inject drugs, migrants, and prisoners, although candidate populations can be expected to vary greatly in different countries and subnational areas.
Affiliations

Citations

Safreed-Harmon, K., Thursz, M., Dillon, J., El-Sayed, M., Elsharkawy, A., Hatzakis, A., Jadoul, M., Prestileo, T., Razavi, H., Rockstroh, J., Wiktor, S., Colombo, M., & Lazarus, J. (2018). The Micro-Elimination Approach to Eliminating Hepatitis C: Strategic and Operational Considerations. Seminars in Liver Disease, 38(3), 1811-1892. https://doi.org/10.1055/s-0038-1666841 (Original work published 2018)